Karl G. Wagner

Prof. Karl G. Wagner

Department of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, Gerhard-Domagk-Str. 3, 53121 Bonn, Germany
orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2004 in Powder Technology
Verified
Journal Article
Closed access
SJS Jonat
S Jonat
SHS Hasenzahl
S Hasenzahl
MDM Drechsler
M Drechsler
PAP Albers
P Albers
Karl G. WagnerKarl G. Wagner
Karl G. Wagner
PSP.C Schmidt
P.C Schmidt

16 January 2019 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
CSChristian Steinebach
Christian Steinebach
HKHannes Kehm
Hannes Kehm
SLStefanie Lindner
Stefanie Lindner
LVLan Phuong Vu
Lan Phuong Vu
SKSimon Köpff
Simon Köpff
Michael GütschowMichael Gütschow
Michael Gütschow
Small-molecule heterobifunctional degraders can effectively control protein levels and are useful research tools.

1 September 2010 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
UHUlrich Heigoldt
Ulrich Heigoldt
FSFlorian Sommer
Florian Sommer
Rolf DanielsRolf Daniels
Rolf Daniels
Karl G. WagnerKarl G. Wagner
Karl G. Wagner

18 May 2016 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
ACAnne Cossé
Anne Cossé
CKCorinna König
Corinna König
ALAlf Lamprecht
Alf Lamprecht
Karl G. WagnerKarl G. Wagner
Karl G. Wagner

11 June 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MMMarius Monschke
Marius Monschke
Karl G. WagnerKarl G. Wagner
Karl G. Wagner
Amorphous solid dispersions (ASDs) have been proven to increase the bioavailability of poorly soluble drugs. It is desirable that the ASD provide a rapid dissolution rate and a sufficient stabilization of the generated supersaturation. In many cases, one polymer alone is not able to provide both features, which raises a need for reasonable polymer combinations. In this study we aimed to generate a rapidly dissolving ASD using the hydrophilic polymer polyvinyl alcohol (PVA) combined with a suitable precipitation inhibitor. Initially, PVA and hydroxypropylmethylcellulose acetate succinate (HPMCAS) were screened for their precipitation inhibitory potential for celecoxib in solution. The generated supersaturation in presence of PVA or HPMCAS was further characterized using dynamic light scattering. Binary ASDs of either PVA or HPMCAS (at 10% and 20% drug load) were prepared by hot-melt extrusion and solid-state analytics were conducted using differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD) and fourier-transformed infrared spectroscopy (FT-IR). The non-sink dissolution studies of the binary ASDs revealed a high dissolution rate for the PVA ASDs with subsequent precipitation and for the HPMCAS ASDs a suppressed dissolution. In order to utilize the unexploited potential of the binary ASDs, the PVA ASDs were combined with HPMCAS either predissolved or added as powder and also formulated as ternary ASD. We successfully generated a solid formulation consisting of the powdered PVA ASD and HPMCAS powder, which was superior in monophasic non-sink dissolution and biorelevant biphasic dissolution studies compared to the binary and ternary ASDs.

1 May 2012 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
JBJ. Buske
J. Buske
CKC. König
C. König
SBS. Bassarab
S. Bassarab
ALA. Lamprecht
A. Lamprecht
SMS. Mühlau
S. Mühlau
Karl G. WagnerKarl G. Wagner
Karl G. Wagner